世界各国のリアルタイムなデータ・インテリジェンスで皆様をお手伝い

強直性脊髄炎:2028年までのアジア太平洋市場の疫学的予測

Axial Spondyloarthritis: Epidemiology Forecast in Asia-Pacific Markets to 2028

 

出版社 出版年月電子版価格 ページ数
GlobalData
グローバルデータ
2019年11月US$3,495
シングルユーザライセンス
39

納品形態:PDF

サマリー

Axial Spondyloarthritis: Epidemiology Forecast in Asia-Pacific Markets to 2028

Summary

Axial spondyloarthritis (AxSpA) is a condition characterized by predominant inflammation in the spine and/or sacroiliac joints, with inflammatory back pain and stiffness that may be improved with exercise. Based on sacroiliac changes on conventional radiographs, AxSpA is classified into radiographic (r-AxSpA) or nonradiographic (nr-AxSpA) depending on the presence or absence of radiographic changes at the sacroiliac joints. Patients traditionally classified as ankylosing spondylitis (AS) would be considered as r-AxSpA. Some of nr-AxSpA progress to AS and some do not (Sieper et al., 2002; Kiltz et al., 2012; Wallis et al., 2013). AS has a genetic association with the HLA-B27 risk allele (Sieper et al., 2002; Dean et al., 2014).

GlobalData epidemiologists selected nationally representative population-based studies that provided data for the diagnosed prevalence of AxSpA in the 5GM. GlobalData’s epidemiological analysis provides country-specific forecasts for the diagnosed prevalent cases of AS and nr-AxSpA in the 5GM during 2018-2028 using two different approaches: forecast based on data obtained through primary market research (PMR) (base scenario), and forecast based on data obtained from secondary research (alternate scenario).

The following data describes diagnosed prevalent cases of AS and nr-AxSpA in the 5GM using base scenario, where the forecast is based on data obtained from PMR. In the 5GM, the diagnosed prevalent cases of AS will increase from 3,472,166 cases in 2018 to 4,28,719 cases in 2028, at an Annual Growth Rate (AGR) of 3.33%, and the diagnosed prevalent cases of nr-AxSpA will increase from 2,579,931 cases in 2018 to 3,375,427 cases in 2028, at an AGR of 3.08%.

Scope

- The Axial Spondyloarthritis Epidemiology Report provides an overview of the risk factors and global trends of AxSpA in the five growth markets (5GM: Australia, China [urban], India, South Korea, and Japan).
- Base Scenario: This report includes a 10-year epidemiological forecast for the diagnosed prevalent cases of AS and nr-AxSpA for both sexes and ages ?18 years in the 5GM.
- Alternate Scenario: Additionally, a 10-year epidemiological forecast for the diagnosed prevalent cases of AS and nr-AxSpA segmented by age (18-19 years, 20-29 years, 30-44 years, 45-59 years, 60-74 years, 75-79 years, 80-84 years, and 85 years and older) and sex. The report also provides the forecast for diagnosed prevalent cases of AS segmented by HLA-B27 seropositivity status in the 5GM.
- The axial spondyloarthritis epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
- The Epidemiology Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 5GM.

Reasons to buy

The AxSpA Epidemiology series will allow you to -
- Develop business strategies by understanding the trends shaping and driving the global AxSpA market.
- Quantify patient populations in the global AxSpA market to improve product design, pricing, and launch plans.
- Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for AxSpA therapeutics in each of the markets covered.
- Understand magnitude of AxSpA by radiographic and nonradiographic population.

目次

Table of Contents

Table of Contents
1.1 List of Tables
1.2 List of Figures
2 Axial Spondyloarthritis: Executive Summary
2.1 Related Reports
2.2 Upcoming Reports
3 Epidemiology
3.1 Disease Background
3.2 Risk Factors and Comorbidities
3.3 Global and Historical Trends
3.4 Forecast Methodology
3.4.1 Sources
3.4.2 Forecast Assumptions and Methods, Diagnosed Prevalent Cases of AS - Base Scenario
3.4.3 Forecast Assumptions and Methods, Diagnosed Prevalent Cases of Nr-AxSpA - Base Scenario
3.4.4 Forecast Assumptions and Methods, Diagnosed Prevalent Cases of AS - Alternative Scenario
3.4.5 Forecast Assumptions and Methods, Diagnosed Prevalent Cases of Nr-AxSpA - Alternative Scenario
3.4.6 Forecast Assumptions and Methods, HLA-B27 Seropositivity Among Diagnosed AS Patients
3.5 Epidemiological Forecast for AS and Nr-AxSpA (2018-2028) - Base Scenario
3.5.1 Diagnosed Prevalent Cases of AS
3.5.2 Diagnosed Prevalent Cases of Nr-AxSpA
3.6 Epidemiological Forecast for AS and Nr-AxSpA (2018-2028) - Alternative Scenario
3.6.1 Diagnosed Prevalent Cases of AS
3.6.2 Age-Specific Diagnosed Prevalent Cases of AS
3.6.3 Sex-Specific Diagnosed Prevalent Cases of AS
3.6.4 Diagnosed Prevalent Cases of AS by HLA-B27 Seropositivity
3.6.5 Diagnosed Prevalent Cases of Nr-AxSpA
3.6.6 Age-Specific Diagnosed Prevalent Cases of Nr-AxSpA
3.6.7 Sex-Specific Diagnosed Prevalent Cases of Nr-AxSpA
3.7 Discussion
3.7.1 Epidemiological Forecast Insight
3.7.2 Limitations of the Analysis
3.7.3 Strengths of the Analysis
4 Appendix

List of Tables

List of Tables
Table 1: Risk Factors and Comorbidities for AS
Table 2: High-Prescribing Physicians (KOL and non-KOLs) Surveyed, By Country

List of Figures

List of Figures
Figure 1: 5GM, Diagnosed Prevalent Cases of AS, Ages ?18 Years, Both Sexes, N, 2018 and 2028 - Base Scenario
Figure 2: 5GM, Diagnosed Prevalent Cases of Nr-AxSpA, Ages ?18 Years, Both Sexes, N, 2018 and 2028 - Base Scenario
Figure 3: 5GM, Diagnosed Prevalence (%) of AxSpA, Both Sexes, Ages ?18 Years, 2008-2028 - Base Scenario
Figure 4: 5GM, Sources Used, Diagnosed Prevalent Cases of AS - Base Scenario
Figure 5: 5GM, Sources Used, Diagnosed Prevalent Cases of Nr-AxSpA - Base Scenario
Figure 6: 5GM, Sources Used, Diagnosed Prevalent Cases of AS - Alternative Scenario
Figure 7: 5GM, Sources Used, Diagnosed Prevalent Cases of Nr-AxSpA - Alternative Scenario
Figure 8: 5GM, Sources Used, HLA-B27 Seropositivity Data Among the Diagnosed Prevalent Cases of AS - Alternative Scenario
Figure 9: 5GM, Diagnosed Prevalent Cases of AS, Ages ?18 Years, Both Sexes, N, 2018 - Base Scenario
Figure 10: 5GM, Diagnosed Prevalent Cases of Nr-AxSpA, Ages ?18 Years, Both Sexes, N, 2018 - Base Scenario
Figure 11: 5GM, Diagnosed Prevalent Cases of AS, Ages ?18 Years, Both Sexes, N, 2018 - Alternative Scenario
Figure 12: 5GM, Age-Specific Diagnosed Prevalent Cases of AS, Both Sexes, N, 2018 - Alternative Scenario
Figure 13: 5GM, Sex-Specific Diagnosed Prevalent Cases of AS, Ages ?18 Years, N, 2018 - Alternative Scenario
Figure 14: 5GM, Diagnosed Prevalent Cases of AS by HLA-B27 Seropositivity, Ages ?18 Years, Both Sexes, N, 2018 - Alternative Scenario
Figure 15: 5GM, Diagnosed Prevalent Cases of Nr-AxSpA, Ages ?18 Years, Both Sexes, N, 2018 - Alternative Scenario
Figure 16: 5GM, Age-Specific Diagnosed Prevalent Cases of Nr-AxSpA, Both Sexes, N, 2018 - Alternative Scenario
Figure 17: 5GM, Sex-Specific Diagnosed Prevalent Cases of Nr-AxSpA, Ages ?18 Years, N, 2018 - Alternative Scenario

 

ページTOPに戻る

あなたが最近チェックしたレポート一覧

  • 最近チェックしたレポートはありません。

お問合は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

webからのお問合せはこちらのフォームから承ります

このレポートへのお問合せ

03-3582-2531

電話お問合せもお気軽に

<無料>メルマガに登録する

 

 

ページTOPに戻る